Should I buy or sell Supernus Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SUPN shares. View SUPN analyst ratings or view top-rated stocks .

What is Supernus Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for Supernus Pharmaceuticals' stock. Their SUPN share price targets range from $41.00 to $41.00. On average, they anticipate the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 42.0% from the stock's current price. View analysts price targets for SUPN or view top-rated stocks among Wall Street analysts .

How have SUPN shares performed in 2024?

Supernus Pharmaceuticals' stock was trading at $28.94 on January 1st, 2024. Since then, SUPN shares have decreased by 0.2% and is now trading at $28.87. View the best growth stocks for 2024 here .

When is Supernus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SUPN earnings forecast .

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its quarterly earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.41 by $0.39. The specialty pharmaceutical company had revenue of $164.30 million for the quarter, compared to analysts' expectations of $155.03 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 0.14% and a net margin of 0.22%. The firm's quarterly revenue was down 1.8% compared to the same quarter last year. During the same period last year, the firm posted $0.43 EPS.

What ETFs hold Supernus Pharmaceuticals' stock?

ETFs with the largest weight of Supernus Pharmaceuticals (NASDAQ:SUPN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , iShares Neuroscience and Healthcare ETF (IBRN) , Invesco S&P SmallCap Health Care ETF (PSCH) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Invesco Nasdaq Future Gen 200 ETF (QQQS) . SPDR S&P 600 Small Cap ETF (SLY) .

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $580.0 million-$620.0 million, compared to the consensus revenue estimate of $622.5 million.

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com . Jack A. Khattar has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA) , AbbVie (ABBV) , Gilead Sciences (GILD) , Alibaba Group (BABA) , Exelixis (EXEL) , Pfizer (PFE) , GW Pharmaceuticals (GWPH) , Netflix (NFLX) , Corcept Therapeutics (CORT) and Cara Therapeutics (CARA) .

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (1.89%), Tributary Capital Management LLC (0.63%), Congress Wealth Management LLC DE (0.32%), Bridge City Capital LLC (0.15%) and Hennion & Walsh Asset Management Inc. (0.07%). Insiders that own company stock include Frank Mottola, Frederick M Hudson, Jack A Khattar, Padmanabh P Bhatt and Tami Tillotson Martin. View institutional ownership trends .

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SUPN

Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

→ Start loving Mondays like this (From DTI) (Ad)

Free SUPN Stock Alerts

$28.87

-0.13 (-0.45%)

(As of 04/18/2024 ET)

Compare

Today's Range: $28.63
▼
$29.48
50-Day Range: $27.11
▼
$35.17
52-Week Range: $21.99
▼
$39.09

Volume: 347,896 shs
Average Volume: 384,721 shs
Market Capitalization: $1.58 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $41.00

Get Supernus Pharmaceuticals alerts:

Supernus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 42.0% Upside
$41.00 Price Target
Short Interest: Bearish
9.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: 0.84
Based on 2 Articles This Week
Insider Trading: Selling Shares
$1.23 M Sold Last Quarter
Proj. Earnings Growth: 26.72%
From $1.16 to $1.47 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

189th out of 919 stocks

Pharmaceutical Preparations Industry

72nd out of 405 stocks

3.5

Analyst's Opinion

Consensus Rating
Supernus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Supernus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.20% of the float of Supernus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Supernus Pharmaceuticals has recently decreased by 2.03%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Supernus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Supernus Pharmaceuticals does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Supernus Pharmaceuticals has received a 58.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topiramate", "Safinamide", "Oxcarbazepine", and "Amantadine" products. See details.
Environmental Sustainability
The Environmental Impact score for Supernus Pharmaceuticals is -2.35.

2.1

News and Social Media Coverage

News Sentiment
Supernus Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Supernus Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for SUPN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Supernus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,227,433.00 in company stock.
Percentage Held by Insiders
Only 8.76% of the stock of Supernus Pharmaceuticals is held by insiders.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Supernus Pharmaceuticals are expected to grow by 26.72% in the coming year, from $1.16 to $1.47 per share.
Price to Book Value per Share Ratio
Supernus Pharmaceuticals has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

Click here and I’ll show you

About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

SUPN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SUPN Stock News Headlines

March 26, 2024 | insidertrades.com

Padmanabh P. Bhatt Sells 14,491 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

March 22, 2024 | insidertrades.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 12,364 Shares

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 15, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)

April 10, 2024 | uk.investing.com

Supernus receives FDA rejection for Parkinson's treatment, submits additional data

April 9, 2024 | yahoo.com

US FDA declines to approve Supernus' Parkinson's combination again (April 8)

April 8, 2024 | finanznachrichten.de

Supernus Pharmaceuticals, Inc.: Supernus Provides Regulatory Update for SPN-830

April 8, 2024 | msn.com

Supernus stock slides as FDA rejects Parkinson's disease infusion device

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 8, 2024 | finance.yahoo.com

Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease

April 8, 2024 | reuters.com

U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease

April 8, 2024 | globenewswire.com

Supernus Provides Regulatory Update for SPN-830

March 21, 2024 | finanznachrichten.de

Supernus Pharmaceuticals, Inc.: Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

March 16, 2024 | investing.com

Supernus Pharmaceuticals executive trades company stock

March 16, 2024 | finance.yahoo.com

SUPN Apr 2024 29.000 call

March 15, 2024 | investing.com

Supernus Pharmaceuticals executive sells over $2.1m in stock

March 6, 2024 | globenewswire.com

Supernus to Participate in Two Upcoming Investor Conferences

March 4, 2024 | seekingalpha.com

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

February 29, 2024 | finance.yahoo.com

Supernus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

February 28, 2024 | globenewswire.com

Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference

February 28, 2024 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)

February 28, 2024 | finance.yahoo.com

Q4 2023 Supernus Pharmaceuticals Inc Earnings Call

February 28, 2024 | finance.yahoo.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript

February 28, 2024 | markets.businessinsider.com

Strong Buy for Supernus Pharmaceuticals on Qelbree’s Robust Sales Growth and Positive Market Outlook

February 27, 2024 | benzinga.com

Recap: Supernus Pharmaceuticals Q4 Earnings

February 27, 2024 | finance.yahoo.com

Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023

February 27, 2024 | globenewswire.com

Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

See More Headlines

Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:SUPN
CUSIP: 86845910
CIK: 1356576
Web: www.supernus.com
Phone: (301) 838-2500
Fax: 301-838-2501
Employees: 652
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $41.00
High Stock Price Target: $41.00
Low Stock Price Target: $41.00
Potential Upside/Downside: +41.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $1.32 million
Net Margins: 0.22%
Pretax Margin: 0.46%
Return on Equity: 0.14%
Return on Assets: 0.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.70
Quick Ratio: 1.43

Sales & Book Value

Annual Sales: $607.52 million
Price / Sales: 2.61
Cash Flow: $1.56 per share
Price / Cash Flow: 18.57
Book Value: $16.87 per share
Price / Book: 1.72

Miscellaneous

Outstanding Shares: 54,740,000
Free Float: 49,940,000
Market Cap: $1.59 billion
Optionable: Optionable
Beta: 0.99

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Jack A. Khattar (Age 63)
Founder, President, CEO, Secretary & Director
Comp: $1.63M
Mr. Timothy C. Dec (Age 65)
Senior VP & CFO
Comp: $635.43k
Dr. Padmanabh P. Bhatt Ph.D. (Age 67)
Chief Scientific Officer & Senior VP of Intellectual Property
Comp: $594.14k
Mr. Frank Mottola (Age 52)
Senior Vice President of Quality, GMP Operations & Information Technology
Comp: $490.87k
Dr. Jonathan Rubin M.D. (Age 63)
MBA, Senior VP of Research & Development and Chief Medical Officer
Comp: $594.65k
Mr. Kevin T. Anderson (Age 62)
Compliance Officer
Dr. Todd Horich M.B.A.
Ph.D., Senior Vice President of Marketing & Market Access
Mr. Taylor Raiford
Senior Vice President of Sales
Dr. Bryan A. Roecklein Ph.D.
Senior Vice President of Corporate Development
Ms. Tami T. Martin Esq. (Age 69)
R.N., Senior Vice President of Regulatory Affairs
Comp: $508.5k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SUPN Stock Analysis - Frequently Asked Questions

Should I buy or sell Supernus Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings or view top-rated stocks.
What is Supernus Pharmaceuticals' stock price target for 2024?: 1 equities research analysts have issued 1-year price objectives for Supernus Pharmaceuticals' stock. Their SUPN share price targets range from $41.00 to $41.00. On average, they anticipate the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 42.0% from the stock's current price.
View analysts price targets for SUPN or view top-rated stocks among Wall Street analysts.
How have SUPN shares performed in 2024?: Supernus Pharmaceuticals' stock was trading at $28.94 on January 1st, 2024. Since then, SUPN shares have decreased by 0.2% and is now trading at $28.87.
View the best growth stocks for 2024 here.
When is Supernus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SUPN earnings forecast.
How were Supernus Pharmaceuticals' earnings last quarter?: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its quarterly earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.41 by $0.39. The specialty pharmaceutical company had revenue of $164.30 million for the quarter, compared to analysts' expectations of $155.03 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 0.14% and a net margin of 0.22%. The firm's quarterly revenue was down 1.8% compared to the same quarter last year. During the same period last year, the firm posted $0.43 EPS.
What ETFs hold Supernus Pharmaceuticals' stock?: ETFs with the largest weight of Supernus Pharmaceuticals (NASDAQ:SUPN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), iShares Neuroscience and Healthcare ETF (IBRN), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Invesco Nasdaq Future Gen 200 ETF (QQQS).SPDR S&P 600 Small Cap ETF (SLY).

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?: Supernus Pharmaceuticals issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $580.0 million-$620.0 million, compared to the consensus revenue estimate of $622.5 million.
What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?: 20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.
What other stocks do shareholders of Supernus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).
Who are Supernus Pharmaceuticals' major shareholders?: Supernus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (1.89%), Tributary Capital Management LLC (0.63%), Congress Wealth Management LLC DE (0.32%), Bridge City Capital LLC (0.15%) and Hennion & Walsh Asset Management Inc. (0.07%). Insiders that own company stock include Frank Mottola, Frederick M Hudson, Jack A Khattar, Padmanabh P Bhatt and Tami Tillotson Martin.
View institutional ownership trends.
How do I buy shares of Supernus Pharmaceuticals?: Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SUPN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial